MX2015015774A - Modulación de la actividad del factor de crecimiento epidérmico de unión a la heparina para curar la membrana timpánica. - Google Patents
Modulación de la actividad del factor de crecimiento epidérmico de unión a la heparina para curar la membrana timpánica.Info
- Publication number
- MX2015015774A MX2015015774A MX2015015774A MX2015015774A MX2015015774A MX 2015015774 A MX2015015774 A MX 2015015774A MX 2015015774 A MX2015015774 A MX 2015015774A MX 2015015774 A MX2015015774 A MX 2015015774A MX 2015015774 A MX2015015774 A MX 2015015774A
- Authority
- MX
- Mexico
- Prior art keywords
- tympanic membrane
- modulation
- growth factor
- sustained release
- epidermal growth
- Prior art date
Links
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 title abstract 2
- 230000035876 healing Effects 0.000 title abstract 2
- 210000003454 tympanic membrane Anatomy 0.000 title abstract 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 238000013268 sustained release Methods 0.000 abstract 4
- 239000012730 sustained-release form Substances 0.000 abstract 4
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010045210 Tympanic Membrane Perforation Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0076—Sprayable compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
- A61F11/20—Ear surgery
- A61F11/202—Surgical middle-ear ventilation or drainage, e.g. permanent; Implants therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/18—Internal ear or nose parts, e.g. ear-drums
- A61F2002/183—Ear parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Acoustics & Sound (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Composite Materials (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan composiciones y métodos para la generación o el tratamiento de perforaciones crónicas en la membrana timpánica mediante la modulación de la actividad del HB-EGF, en los métodos de la invención, una membrana timpánica perforada crónicamente se pone en contacto tópicamente con una dosis eficaz de factor de crecimiento epidérmico de unión a la heparina, HB-EGF, o un agente que tiene actividad de HB-EGF durante un periodo suficiente para proporcionar una curación mejorada de la perforación de la membrana; en algunas modalidades la dosis HB-EGF se proporciona en una formulación de liberación sostenida; en otra modalidades se proporciona la administración regular de una formulación de liberación sostenida no sostenida; en algunas modalidades la liberación sostenida está provista por un dispositivo, por ejemplo una bomba u otro dispositivo de liberación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361823749P | 2013-05-15 | 2013-05-15 | |
PCT/US2014/033536 WO2014186075A2 (en) | 2013-05-15 | 2014-04-09 | Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015015774A true MX2015015774A (es) | 2016-07-26 |
Family
ID=51898980
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015015774A MX2015015774A (es) | 2013-05-15 | 2014-04-09 | Modulación de la actividad del factor de crecimiento epidérmico de unión a la heparina para curar la membrana timpánica. |
MX2020001319A MX2020001319A (es) | 2013-05-15 | 2015-11-13 | Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001319A MX2020001319A (es) | 2013-05-15 | 2015-11-13 | Modulacion de la actividad del factor de crecimiento epidermico de union a la heparina para curar la membrana timpanica. |
Country Status (27)
Country | Link |
---|---|
US (3) | US20160074476A1 (es) |
EP (2) | EP2996709B1 (es) |
JP (1) | JP6316943B2 (es) |
KR (1) | KR102318748B1 (es) |
CN (2) | CN113559242A (es) |
AU (2) | AU2014265901B2 (es) |
BR (2) | BR122020011229B1 (es) |
CA (1) | CA2912411C (es) |
CY (1) | CY1123464T1 (es) |
DK (1) | DK2996709T3 (es) |
ES (1) | ES2805002T3 (es) |
HK (1) | HK1217166A1 (es) |
HR (1) | HRP20200971T1 (es) |
HU (1) | HUE049294T2 (es) |
IL (2) | IL242454B (es) |
LT (1) | LT2996709T (es) |
MX (2) | MX2015015774A (es) |
PH (2) | PH12015502577A1 (es) |
PL (1) | PL2996709T3 (es) |
PT (1) | PT2996709T (es) |
RS (1) | RS60412B1 (es) |
RU (2) | RU2676483C2 (es) |
SG (1) | SG11201509347UA (es) |
SI (1) | SI2996709T1 (es) |
UA (1) | UA120037C2 (es) |
WO (1) | WO2014186075A2 (es) |
ZA (1) | ZA201508289B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102634748B1 (ko) | 2018-06-15 | 2024-02-13 | 삼성전자주식회사 | 포토 마스크용 펠리클 및 이의 제조 방법 |
KR20220041143A (ko) | 2019-07-31 | 2022-03-31 | 아스텔라스세이야쿠 가부시키가이샤 | 귀내 투여용의 의약 조성물 |
JPWO2022065404A1 (es) | 2020-09-25 | 2022-03-31 | ||
US11984398B2 (en) | 2021-03-08 | 2024-05-14 | Changxin Memory Technologies, Inc. | Semiconductor structure and manufacturing method thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5529914A (en) | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
WO1993009176A2 (en) | 1991-10-29 | 1993-05-13 | Clover Consolidated, Limited | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
US6514533B1 (en) * | 1992-06-11 | 2003-02-04 | Alkermas Controlled Therapeutics, Inc. | Device for the sustained release of aggregation-stabilized, biologically active agent |
US5827937A (en) | 1995-07-17 | 1998-10-27 | Q Med Ab | Polysaccharide gel composition |
EP0914168A1 (en) | 1996-05-03 | 1999-05-12 | Innogenetics N.V. | New medicaments containing gelatin cross-linked with oxidized polysaccharides |
WO1999017820A1 (en) | 1997-10-03 | 1999-04-15 | Texas Pharmaceuticals, Inc. | Improved dual chamber syringe apparatus |
US5971953A (en) | 1998-01-09 | 1999-10-26 | Bachynsky; Nicholas | Dual chamber syringe apparatus |
US6191109B1 (en) * | 1997-10-31 | 2001-02-20 | Children's Hospital, Inc. | Methods of treating intestinal ischemia using heparin-binding epidermal growth factor |
BR9909717A (pt) * | 1998-04-17 | 2000-12-26 | Angiogenix Inc | Fatores angiogênicos terapêuticos e métodos para seu uso |
WO2001047584A1 (en) | 1999-12-28 | 2001-07-05 | Asger Lau Dalmose | Dual chamber syringe with a dual function piston |
AU2001239549A1 (en) | 2000-03-24 | 2001-10-03 | Akzo Nobel N.V. | Keratinocyte growth inhibitors and hydroxamic acid derivatives |
US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
US7220431B2 (en) | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
US20090148486A1 (en) * | 2005-04-28 | 2009-06-11 | Helen Lu | Compositions and methods for treating pulp inflammations caused by infection or trauma |
KR20080026198A (ko) * | 2005-06-30 | 2008-03-24 | 안트로제네시스 코포레이션 | 태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원 |
EP1949907B1 (en) | 2005-09-28 | 2014-07-02 | Kagoshima University | Novel application of heparin-binding epidermal growth factor-like growth factor for medical purposes |
WO2008134635A1 (en) | 2007-04-30 | 2008-11-06 | Nationwide Children's Hospital | Heparin binding epidermal growth factor (hb-egf) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation |
US20090192079A1 (en) * | 2007-10-09 | 2009-07-30 | Genzyme Corporation | Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen |
US20110142819A1 (en) * | 2008-01-22 | 2011-06-16 | Omnio Healer Ab | Method of improving would healing |
US8822410B2 (en) * | 2008-05-19 | 2014-09-02 | Children's Medical Center Corporation | Tympanic membrane permeating ear drops and uses thereof |
EP2353547B1 (en) * | 2008-06-26 | 2018-01-17 | Nobelpharma Co., Ltd. | Agent for regenerating tympanic membrane or external auditory canal |
AU2010285974A1 (en) * | 2009-08-17 | 2012-03-22 | Forerunner Pharma Research Co., Ltd. | Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient |
CN103037892A (zh) * | 2010-02-22 | 2013-04-10 | 布里格姆妇女医院 | 诱导血管生成的组合物和方法 |
US8556854B2 (en) | 2010-07-22 | 2013-10-15 | Becton, Dickinson And Company | Dual chamber syringe with retractable needle |
EP2731549B1 (en) | 2011-07-11 | 2021-09-15 | Ear Science Institute Australia | Device for ear drum repair |
US9821118B2 (en) | 2011-09-02 | 2017-11-21 | Unl Holdings Llc | Automatic reconstitution for dual chamber syringe |
WO2014004936A1 (en) * | 2012-06-28 | 2014-01-03 | The Administrators The Tulane Educational Fund | Selectively polymerizable compositions and methods of use in vivo |
JP2016525374A (ja) | 2013-04-09 | 2016-08-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 架橋キトサン−ラクチドヒドロゲル |
-
2014
- 2014-04-09 SI SI201431624T patent/SI2996709T1/sl unknown
- 2014-04-09 HU HUE14798587A patent/HUE049294T2/hu unknown
- 2014-04-09 PT PT147985873T patent/PT2996709T/pt unknown
- 2014-04-09 MX MX2015015774A patent/MX2015015774A/es active IP Right Grant
- 2014-04-09 CN CN202110777625.9A patent/CN113559242A/zh active Pending
- 2014-04-09 LT LTEP14798587.3T patent/LT2996709T/lt unknown
- 2014-04-09 BR BR122020011229-8A patent/BR122020011229B1/pt active IP Right Grant
- 2014-04-09 US US14/888,936 patent/US20160074476A1/en not_active Abandoned
- 2014-04-09 DK DK14798587.3T patent/DK2996709T3/da active
- 2014-04-09 SG SG11201509347UA patent/SG11201509347UA/en unknown
- 2014-04-09 KR KR1020157034839A patent/KR102318748B1/ko active IP Right Grant
- 2014-04-09 WO PCT/US2014/033536 patent/WO2014186075A2/en active Application Filing
- 2014-04-09 UA UAA201511095A patent/UA120037C2/uk unknown
- 2014-04-09 CA CA2912411A patent/CA2912411C/en active Active
- 2014-04-09 RU RU2015148636A patent/RU2676483C2/ru active
- 2014-04-09 JP JP2016513956A patent/JP6316943B2/ja active Active
- 2014-04-09 EP EP14798587.3A patent/EP2996709B1/en active Active
- 2014-04-09 ES ES14798587T patent/ES2805002T3/es active Active
- 2014-04-09 RS RS20200686A patent/RS60412B1/sr unknown
- 2014-04-09 BR BR112015028367-5A patent/BR112015028367B1/pt active IP Right Grant
- 2014-04-09 RU RU2018146249A patent/RU2018146249A/ru not_active Application Discontinuation
- 2014-04-09 PL PL14798587T patent/PL2996709T3/pl unknown
- 2014-04-09 EP EP20165704.6A patent/EP3708181A1/en not_active Withdrawn
- 2014-04-09 AU AU2014265901A patent/AU2014265901B2/en active Active
- 2014-04-09 CN CN201480034653.XA patent/CN105555296A/zh active Pending
-
2015
- 2015-11-04 IL IL242454A patent/IL242454B/en active IP Right Grant
- 2015-11-10 ZA ZA2015/08289A patent/ZA201508289B/en unknown
- 2015-11-13 MX MX2020001319A patent/MX2020001319A/es unknown
- 2015-11-13 PH PH12015502577A patent/PH12015502577A1/en unknown
-
2016
- 2016-04-08 HK HK16104038.8A patent/HK1217166A1/zh unknown
-
2018
- 2018-05-16 US US15/981,642 patent/US11235027B2/en active Active
-
2019
- 2019-01-31 AU AU2019200630A patent/AU2019200630B2/en active Active
-
2020
- 2020-03-16 IL IL273329A patent/IL273329B/en active IP Right Grant
- 2020-06-19 HR HRP20200971TT patent/HRP20200971T1/hr unknown
- 2020-07-23 CY CY20201100675T patent/CY1123464T1/el unknown
- 2020-07-24 PH PH12020551126A patent/PH12020551126A1/en unknown
-
2021
- 2021-12-20 US US17/556,193 patent/US11963998B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
PH12015500115B1 (en) | Glucagon analogues | |
BR112016014410A2 (pt) | terapia de combinação com vacina de neoantígeno | |
CL2012003745A1 (es) | Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
UA111148C2 (uk) | Сигма-ліганди для застосування при профілактиці і/або лікуванні післяопераційного болю | |
TN2016000084A1 (en) | Nsaid and sigma receptor ligand combinations | |
PH12015502577A1 (en) | Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing | |
MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
FI20115135A (fi) | Mikrofibrilloidun selluloosan tulehduksia estävä vaikutus | |
ITMI20120370A1 (it) | Miscela antimicrobica e rivestimento per supportare la guarigione di ferite, che ha un effetto antimicrobico. | |
CO6551731A2 (es) | Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica | |
MX2016007286A (es) | Combinaciones de gabapentinoides y ligandos de receptores sigma. | |
GT201200345A (es) | Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica | |
PH12015502282A1 (en) | Alpha-2 adrenoceptor and sigma receptor ligand combinations | |
CL2015002817A1 (es) | Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca). | |
MX359713B (es) | Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas. | |
UY34543A (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica. | |
CY1122538T1 (el) | Συμπλεγματα χονδροϊτινης για διαδερμικη απορροφηση | |
EA201690445A1 (ru) | Лечение рака | |
CY1118633T1 (el) | Χρηση pidotimod για την θεραπευτικη αγωγη ατοπικης δερματιτιδας | |
EA201690551A1 (ru) | Применение гидроксипропил хитозана для лечения онихомикоза | |
EA201690709A1 (ru) | Применение одипарцила в лечении мукополисахаридоза | |
EA201492173A1 (ru) | Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |